

Table S1. Baseline characteristics at the start of TOMORROW period 1

	Placebo (n=85)	Nintedanib			
		50 mg qd (n=86)	50 mg bid (n=86)	100 mg bid (n=86)	150 mg bid (n=85)
Male, n (%)	63 (74.1)	65 (75.6)	62 (72.1)	65 (75.6)	65 (76.5)
Age, years, mean (SD)	64.8 (8.6)	65.3 (9.4)	64.9 (8.5)	65.1 (8.6)	65.4 (7.8)
Smoking history, n (%)					
Never smoked	28 (32.9)	27 (31.4)	29 (33.7)	32 (37.2)	25 (29.4)
Ex/current-smoker	57 (67.1)	59 (68.6)	57 (66.3)	54 (62.8)	60 (70.6)
Time since diagnosis, years, mean (SD)	1.4 (1.5)	1.4 (1.3)	1.1 (1.2)	1.2 (1.2)	1.0 (1.2)
FVC, L, mean (SD)	2.8 (0.8)	2.8 (0.8)	2.7 (0.7)	2.9 (0.8)	2.7 (0.8)
FVC, % predicted, mean (SD)	81.7 (17.6)	80.4 (17.8)	79.8 (15.8)	85.5 (19.2)	79.1 (18.5)
SpO ₂ , %, mean (SD)	95.3 (2.2)	95.0 (2.7)	95.4 (2.2)	95.3 (2.0)	95.6 (1.7)
DLco, % predicted, mean (SD)	48.4 (12.9)	46.2 (13.6)	46.6 (12.7)	48.7 (12.8)	47.5 (11.0)

Table S2. Summary of exposure to actual treatment dose received across TOMORROW periods 1 and 2 and the open-label extension trial

Randomised treatment in TOMORROW period 1	Actual treatment dose received	N	Duration of exposure (months)	
			Mean (SD)	Median (range)
Placebo	Placebo	85	10.6 (3.0)	11.9 (0.3, 12.4)
Placebo	Nintedanib 50 mg qd	53	12.7 (6.2)	12.0 (2.6, 27.1)
Placebo	Nintedanib 50 mg bid*	2	10.3 (2.8)	10.3 (8.3, 12.3)
Placebo	Nintedanib 100 mg bid	11	15.8 (15.8)	13.3 (0.2, 52.6)
Placebo	Nintedanib 150 mg bid	35	17.5 (18.2)	8.3 (0.1, 55.8)
Placebo	Off-treatment [†]	25	2.0 (1.3)	2.0 (0.3, 6.0)
Nintedanib 150 mg bid	Nintedanib 150 mg bid	85	21.4 (24.1)	12.0 (0.1, 86.1)
Nintedanib 150 mg bid	Nintedanib 100 mg bid	28	18.3 (21.2)	6.8 (0.3, 68.9)
Nintedanib 150 mg bid	Off-treatment [†]	24	2.4 (2.2)	1.6 (0.4, 8.9)

*Two patients were mistakenly marked as reduced dose at the end of TOMORROW period 1 and continued on 50 mg bid. [†]Duration off-treatment was calculated as the sum of all treatment interruptions. Of the 35 patients who increased their dose to nintedanib 150 mg bid, 11 had ≥ 1 dose reduction to 100 mg bid during the extension trial. Of the 35 patients in the nintedanib 150 mg bid group who entered the extension trial, three had ≥ 1 dose reduction to 100 mg bid in the extension trial.

Table S3. Patient characteristics at the start of the open-label extension trial

	Nintedanib 150 mg bid (n=35)	Comparator (n=37)
Male, n (%)	28 (80.0)	23 (62.2)
Age, years, mean (SD)	67.2 (7.0)	66.2 (7.3)
Smoking history, n (%)		
Never smoked	12 (34.3)	14 (37.8)
Ex/current-smoker	23 (65.7)	23 (62.2)
Time since diagnosis, years, mean (SD)	2.9 (1.1)	3.5 (1.6)
FVC, L, mean (SD)	2.7 (0.9)	2.4 (0.7)
FVC, % predicted, mean (SD)	77.1 (21.4)	73.0 (17.9)
DLco, % predicted, mean (SD)	40.1 (14.4)	38.9 (10.5)

Data based on information collected at visit 1 in the open-label extension trial. Patients in the comparator group received placebo in period 1 of the TOMORROW trial and nintedanib 50 mg qd in period 2. Patients entered the extension trial on the dose that they were receiving at the end of period 2, but had the option to increase dose to nintedanib 150 mg bid. Dose reduction from 150 mg bid to 100 mg bid and treatment interruption were permitted for the management of adverse events.

Table S4. Exposure over TOMORROW periods 1 and 2 and the open-label extension trial

	Nintedanib 150 mg bid (n=85)	Comparator* (n=85)
Exposure, months		
Mean (SD)	27.6 (26.5)	28.1 (23.1)
Minimum, maximum	0.1, 86.1	0.3, 92.8
Exposure by category, n (%)		
≤3 months	10 (11.8)	6 (7.1)
>3 to ≤6 months	10 (11.8)	2 (2.4)
>6 to ≤12 months	16 (18.8)	20 (23.5)
>12 to ≤13 months	2 (2.4)	3 (3.5)
>13 months	47 (55.3)	54 (63.5)

*Patients in the comparator group received placebo in TOMORROW period 1 and nintedanib 50 mg qd in period 2. Patients entered the extension trial on the dose that they were receiving at the end of period 2, but had the option to increase dose to 150 mg bid. Dose reduction from 150 mg bid to 100 mg bid and treatment interruption were permitted for the management of adverse events.

Table S5. Exposure by trial and treatment

Trial(s)	Treatment	N	Duration of exposure (months)	
			Mean (SD)	Median (range)
TOMORROW period 1	Placebo	85	10.6 (3.0)	11.9 (0.3, 12.4)
	Nintedanib 150 mg bid	85	9.5 (3.7)	11.7 (0.1, 12.8)
TOMORROW period 2	Nintedanib 50 mg qd	54	6.9 (4.9)	5.9 (0.5, 18.0)
	Nintedanib 150 mg bid	48	5.1 (2.9)	5.2 (0.8, 10.0)
TOMORROW periods 1 and 2	Comparator	85	16.8 (7.8)	18.2 (0.3, 32.9)
	Nintedanib 150 mg bid	85	14.2 (7.8)	16.1 (0.1, 26.0)
TOMORROW periods 1 and 2 and open-label extension trial	Comparator	85	28.1 (23.1)	21.6 (0.3, 92.8)
	Nintedanib 150 mg bid	85	27.6 (26.5)	16.1 (0.1, 86.1)
TOMORROW periods 1 and 2 and open-label extension trial, including only patients who entered the open-label extension trial	Comparator	37	48.5 (20.7)	43.4 (19.6, 92.8)
	Nintedanib 150 mg bid	35	54.0 (21.7)	43.3 (25.4, 86.1)

Data from patients randomised in TOMORROW period 1 unless otherwise stated. Patients in the comparator group received placebo in period 1 of the TOMORROW trial and nintedanib 50 mg qd in period 2. Patients entered the extension trial on the dose that they were receiving at the end of period 2,

but had the option to increase dose to nintedanib 150 mg bid. Dose reduction from 150 mg bid to 100 mg bid and treatment interruption were permitted for the management of adverse events.